Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Aziyo Biologics, Inc. specializes in regenerative medicine, focusing on the development of biologic products for surgical applications, particularly in the orthopedic and wound care markets. The company's unique competitive advantage lies in its proprietary technology for processing human tissue, which enhances healing and reduces complications in surgical procedures.
Aziyo generates revenue primarily through the sale of its regenerative tissue products, which are marketed to hospitals and surgical centers. The company leverages its proprietary tissue processing technology to differentiate its offerings, allowing for premium pricing and strong margins despite competitive pressures.
Regulatory approvals for new products
Market adoption rates of regenerative medicine solutions
Partnerships or collaborations with healthcare providers
Changes in reimbursement policies for biologic products
Regulatory changes impacting the approval process for medical devices
Technological disruption from new entrants in the regenerative medicine space
Increased competition from larger medical device companies entering the regenerative market
Pricing pressures from generic alternatives
Negative cash flow impacting liquidity and operational flexibility
Potential need for additional capital raises to fund operations
moderate - The demand for medical devices can fluctuate with economic conditions, impacting elective surgeries and healthcare spending.
Higher interest rates could increase financing costs for the company, impacting its ability to invest in R&D and growth initiatives, potentially leading to lower valuation multiples.
minimal - The company has a low debt-to-equity ratio, indicating limited reliance on external financing.
growth - Investors seeking exposure to innovative medical technologies and potential high returns from market expansion.
high - The stock has exhibited significant price volatility, as evidenced by a 78.7% decline over the past year.
